Testosterone Cypionate/Enanthate injectable — Class II drug recall D-1164-2018
Terminated recall by Auro Pharmacies, Inc., reported 2018-09-05, distributed nationwide. Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intende
| Recall number | D-1164-2018 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Auro Pharmacies, Inc., La Habra, CA, United States |
| Recall initiated | 2018-08-21 |
| Classified | 2018-08-29 |
| Reported by FDA | 2018-09-05 |
| Terminated | 2020-01-30 |
| Distributed | Nationwide (US) |
| Quantity | 32 vials |
| Reason classes | sterility |
| Lot numbers | 180606/18 |
| Expiration dates | 2018-11-30 |
Product
Testosterone Cypionate/Enanthate injectable, 200/50 mg/mL, packaged in a) 5 mL and 8 mL Multiple Dose vials, Rx only, Central Drugs Compounding Pharmacy, 520 W. La Habra Blvd, La Habra, CA 90631
Reason for recall
Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1164-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.